The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cabozantinib plus atezolizumab in locally advanced/metastatic adrenocortical carcinoma: Results from a multi-cohort basket phase II trial, CABATEN/GETNE-T1914.
 
Enrique Grande
Honoraria - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Dr. Reddy's Laboratories; Eisai; Eusa Pharma; EUSA Pharma; GlaxoSmithKline; IPSEN; Janssen-Cilag; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; MSD; Pfizer; Roche; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ipsen (Inst); Lexicon (Inst); Molecular Templates (Inst); Pfizer (Inst); Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Pfizer; Roche/Genentech
 
Marta Benavent Viñuales
No Relationships to Disclose
 
Javier Molina-Cerrillo
No Relationships to Disclose
 
Alex Teule
Consulting or Advisory Role - Advanced Accelerator Applications; Esteve; IPSEN,; Pfizer
Speakers' Bureau - Advanced Accelerator Applications; AstraZeneca; IPSEN,; Novartis; Pfizer
Other Relationship - ENETS; Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE); Spanish Association of Medical Oncology (SEOM)
 
Paula Jimenez-Fonseca
Speakers' Bureau - BMS GmbH & Co. KG; Lilly
Other Relationship - IPSEN
 
Alberto Carmona-Bayonas
No Relationships to Disclose
 
Carlos López
Honoraria - Advanced Accelerator Applications; AstraZeneca; Bayer; Bristol Myers Squibb; Eisai; Ipsen; Merck; MSD Oncology; Novartis; Pfizer; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Eisai; Ipsen; Merck; Pfizer; Roche; Sanofi; SERVIER
Research Funding - Amgen; AstraZeneca Spain; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Ipsen; Merck; Merck Sharp & Dohme; Roche; Sanofi
Travel, Accommodations, Expenses - Amgen; Ipsen; Merck; Pfizer; Roche; SERVIER
 
Rocio Garcia-Carbonero
Honoraria - Advanced Accelerator Applications; Amgen; AstraZeneca (I); Bayer; BMS; Boehringer Ingelheim; Esteve; Gilead Sciences (I); Hutchmed; Ipsen; Lilly (I); Merck; Midatech Pharma; Mirati Therapeutics (I); MSD; Novartis; Pfizer (I); PharmaMar; Roche (I); Sanofi (I); Servier; Takeda (I)
Consulting or Advisory Role - HMP
Research Funding - BMS (Inst); MSD (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Advanced Accelerator Applications/Novartis; Esteve; Ipsen; Merck; MSD
 
Cinta Hierro
Speakers' Bureau - Lilly; MSD
Research Funding - Merck
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Roche
Other Relationship - ALX Oncology; AstraZeneca; Bristol-Myers Squibb; Zymeworks
 
Ana Custodio
No Relationships to Disclose
 
Javier Martinez-Trufero
Consulting or Advisory Role - Boehringer Ingelheim Spain; Deciphera; Eisai; PharmaMar; Qinlock; Qinlock
Research Funding - Blueprint Medicines (Inst); Lilly (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Merck; PharmaMar
 
Marta Llanos
Consulting or Advisory Role - Amgen; Roche
Speakers' Bureau - Advanced Accelerator Applications; Amgen; Bristol-Myers Squibb; Eisai; IPSEN,; Lilly; Merck; Roche; Sanofi; SERVIER
 
Isabel Sevilla
Consulting or Advisory Role - Advanced Accelerator Applications; Advanz Pharma; Amgen; Boehringer Ingelheim; Esteve; IPSEN,; Pfizer; PharmaMar; Syrtex
Speakers' Bureau - Advanced Accelerator Applications; Amgen; Bayer; Boehringer Ingelheim; IPSEN,; Pfizer; PharmaMar; Pierre Fabre
Other Relationship - Global Emerging Infections Surveillance; Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
 
Jorge Hernando
No Relationships to Disclose
 
Inmaculada Gallego Jimenez
No Relationships to Disclose
 
Teresa Alonso-Gordoa
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Lilly; MSD Oncology; Pfizer
Research Funding - Ipsen; Janssen Oncology
Travel, Accommodations, Expenses - Janssen Oncology
 
Javier Gallego
No Relationships to Disclose
 
Jaume Capdevila
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Eisai; Esteve; Exelixis; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Sanofi
Speakers' Bureau - Bayer; Eisai; Esteve; Hutchison MediPharma; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Ipsen (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Eisai; Ipsen; Pfizer